Servier agreed to acquire Day One Biopharmaceuticals for roughly $2.5 billion, securing Ojemda (tovorafenib), an FDA‑approved therapy for pediatric low‑grade glioma, and an early‑to‑late-stage oncology pipeline. Company statements and filings show Servier will fund the purchase with cash and investments, and Day One’s shares jumped on the premium offer. Servier’s U.S. CEO David Lee framed the deal as a strategic push into rare cancers, aligning Ojemda with the company’s existing pediatric brain-tumor assets. The transaction consolidates a marketed pediatric oncology product with development-stage programs across adult and pediatric solid tumors.